Newswise
Cure8 news brief
Why This Matters
Chronic visceral pain is common in people with IBD and IBS and current treatments often do not address nerve pathways that drive pain. Research aiming to target pain-signalling could eventually lead to more effective, mechanism-based treatments rather than symptom relief alone.
The program’s focus on patient-derived models and novel biologic approaches (venom peptides, engineered proteins) signals new therapeutic directions that could matter to people with persistent abdominal pain.
Who Should Pay Attention
People with IBD or IBS who experience chronic visceral pain; clinicians who manage IBD/IBS-related pain; researchers and industry working on pain therapeutics and drug discovery.
Study Snapshot
Story typeResearch news
Evidence typePress release
Source depthMetadata only
What To Know
A five-year NHMRC-funded research program at Adelaide University led by Professor Stuart Brierley will study mechanisms of chronic visceral pain linked to IBS, IBD and endometriosis and test targeted therapies (including venom-derived peptides and engineered proteins) to interrupt pain-signalling between the gut and the brain.
The project will use clinically validated animal and patient-derived laboratory models and involves international researchers, industry partners, and people with lived experience.
The report is an announcement-style news release describing the program’s goals and planned research approaches; it does not present clinical trial results or specific treatment outcomes. It appears grounded in the source news release rather than a peer-reviewed paper.
Keep In Mind
This is a research program announcement (NHMRC-funded) describing planned investigations and therapeutic development; it does not report completed clinical trials or proven treatments. Translating basic and preclinical findings into safe, effective patient therapies typically takes many years and further testing including clinical trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Press release
Evidence type derived from source or registry metadata.
PublicationNewswise
PublisherNewswise MedNews RSS
AuthorsAdelaide University
Indexed viaNewswise
Source typeResearch news
PublishedAug 10, 2026, 8:40 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Novel Human Intestinal Organoid Platform with Peristaltic Function for Drug Discovery and Pre-Clinical Testing in GI Motility Disorders
A validated human peristaltic intestinal organoid model could make preclinical testing more predictive for drugs affecting gut motility and reduce reliance on animal models.
What Causes Crohn's Disease Symptoms When Inflammation Isn't Present? - HealthCentral
This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...
Impact of Diet on Symptomatic Hereditary Alpha-Tryptasemia
People with HαT report GI symptoms often labeled IBS; this study aims to test whether intestinal barrier dysfunction and specific food proteins trigger mucosal and mast-cell responses that could explain symptoms. If...